New chimeric RNAs in acute myeloid leukemia
Open Access
- 2 August 2017
- journal article
- Published by F1000 Research Ltd in F1000Research
- Vol. 6, 1302
Abstract
Background: High-throughput next generation sequencing (NGS) technologies enable the detection of biomarkers used for tumor classification, disease monitoring and cancer therapy. Whole-transcriptome analysis using RNA-seq is important, not only as a means of understanding the mechanisms responsible for complex diseases but also to efficiently identify novel genes/exons, splice isoforms, RNA editing, allele-specific mutations, differential gene expression and fusion-transcripts or chimeric RNA (chRNA). Methods: We used Crac, a tool that uses genomic locations and local coverage to classify biological events and directly infer splice and chimeric junctions within a single read. Crac’s algorithm extracts transcriptional chimeric events irrespective of annotation with a high sensitivity, and CracTools was used to aggregate, annotate and filter the chRNA reads. The selected chRNA candidates were validated by real time PCR and sequencing. In order to check the tumor specific expression of chRNA, we analyzed a publicly available dataset using a new tag search approach. Results: We present data related to acute myeloid leukemia (AML) RNA-seq analysis. We highlight novel biological cases of chRNA, in addition to previously well characterized leukemia chRNA. We have identified and validated 17 chRNAs among 3 AML patients: 10 from an AML patient with a translocation between chromosomes 15 and 17 (AML-t(15;17), 4 from patient with normal karyotype (AML-NK) 3 from a patient with chromosomal 16 inversion (AML-inv16). The new fusion transcripts can be classified into four groups according to the exon organization. Conclusions: All groups suggest complex but distinct synthesis mechanisms involving either collinear exons of different genes, non-collinear exons, or exons of different chromosomes. Finally, we check tumor-specific expression in a larger RNA-seq AML cohort and identify new AML biomarkers that could improve diagnosis and prognosis of AML.Keywords
Funding Information
- Agence Nationale de la Recherche (ANR-10-INBS-09)
- Fondation pour la Recherche Médicale (DBI20131228566)
- Ligue Nationale Contre le Cancer (EL2015.LNCC/JML)
This publication has 32 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Evidence for Transcript Networks Composed of Chimeric RNAs in Human CellsPLOS ONE, 2012
- International network of cancer genome projectsNature, 2010
- Atypical mRNA fusions in PML‐RARA positive, RARA‐PML negative acute promyelocytic leukemiaGenes, Chromosomes and Cancer, 2010
- Implications of chimaeric non-co-linear transcriptsNature, 2009
- Chimeric transcript discovery by paired-end transcriptome sequencingProceedings of the National Academy of Sciences, 2009
- SLC45A3-ELK4 Is a Novel and Frequent Erythroblast Transformation–Specific Fusion Transcript in Prostate CancerCancer Research, 2009
- Transcriptome sequencing to detect gene fusions in cancerNature, 2009
- Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivityBlood, 2007
- Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer ProgramLeukemia, 2003